Evaxion Biotech

Company profile

About Evaxion Biotech

Evaxion Biotech is a pioneering TechBio company leveraging its proprietary AI-Immunology™ platform for rapid vaccine target discovery, drug design, and development. The company's mission is to decode the human immune system to develop novel vaccines for cancer and infectious diseases. The AI-Immunology™ platform is clinically validated and uses artificial intelligence and machine learning to simulate the human immune system, generating predictive models that identify therapeutically relevant vaccine targets within 24 hours. In oncology, Evaxion creates truly personalized therapies tailored to individual patients, while in infectious diseases, the technology designs next-generation vaccines to address unmet medical needs. The platform consists of multiple proprietary AI building blocks including PIONEER™, EDEN™, ObsERV™, and RAVEN™ that can be intelligently combined to generate tailored AI prediction models for complex immune-related healthcare challenges. Evaxion maintains a broad pipeline of candidates with potential to revolutionize cancer prevention and treatment as well as infectious disease management. The company operates state-of-the-art facilities with multidisciplinary capabilities spanning AI immuno-informatics, animal facilities, laboratories, translational medicine, clinical development, and vaccine manufacturing. Since 2021, Evaxion has been publicly traded on the Nasdaq Capital Market under ticker EVAX. The company is headquartered in Hørsholm, Denmark, and pursues a multi-partner business model focused on vaccine target discovery, drug design, and development agreements with leading organizations.

Company description · Evaxion Biotech official website